TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants will be ≥ 18 years of age~* Biopsy proven glioblastoma~* Must meet one of the following criteria:~* Recent surgery (within 2 months) showing recurrent glioblastoma with measurable (20 mm in 2 dimensions) residual tumor.~Radiologic evidence of recurrent tumor based on conventional and advanced MRI findings.~* Recommended for clinically indicated bevacizumab therapy~* Life expectancy of greater than 3 months in the opinion of an investigator or treating physician.~* Karnofsky performance status ≥ 60~* Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.~Exclusion Criteria:~* Inability to tolerate imaging procedures in the opinion of an investigator or treating physician~* Females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential at screening.~* Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study~* Less than 3 months from finishing the most recent radiation or immunotherapy.~* Contraindications to MRI or use of gadolinium contrast~* Only individuals (aged 18 or over) who can understand and give informed consent will be approached to participate in this study. Individuals who are considered to be mentally disabled will not be recruited for this study. All subjects must understand and be able to give informed consent. We will not be using specific methods to assess decisional capacity. Economically disadvantaged persons will not be vulnerable to undue influence, as this study offers no compensation. All individuals will be told that their choice regarding study participation will in no way change their access to clinical care. This should negate any undue influence or coercion. Pregnant women, children, fetuses, neonates, or prisoners are not included in this research study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Timing of PDA Closure and Respiratory Outcome in Premature Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inborn patients at JHS hospitals (admitted to the NICU at JMH within the first 72 hrs of age~* BW 500-1250 grams~* 23-32 wks gestational age~* \> 1d but \< 14d of age.~Exclusion Criteria:~* Major congenital malformations~* Proven sepsis (positive blood culture)~* Contraindications to the use of Ibuprofen or Indomethacin~* Terminal condition, not expected to survive beyond 48 h~* Infants born excessively SGA(3 S.D. below the mean for GA)~* Infants with initial PDA presentation that is hemodynamically significant

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 14 Days
- Healthy Volunteers: f

Study Arms:
- early ibuprofen (Type: EXPERIMENTAL): Drug: Early ibuprofen~IBUPROFEN DOSING SCHEDULE: At the diagnosis of PDA, infants randomized to early treatment will receive blinded ibuprofen initial dose 10 mg/kg, then two doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Initial therapy will be blinded. This group will then be eligible to receive unblinded, open label ibuprofen for a hemodynamically significant PDA include: SIGNS OF PDA + Presence of significant pulmonary hemorrhage ALONE OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (not due to something other than PDA) defined as at least two of the following respirator settings: Need for supplemental O2 \> 50%; need IMV \>40; need for PIP \> 20; or need for HFOV.
- Late Ibuprofen expectant group (placebo) (Type: OTHER): Late ibuprofen expectant group (placebo): Ibuprofen schedule: At PDA diagnosis, infants randomized to late expectant group will receive blinded placebo. If hemo-dynamically significant PDA develops, infants now receive open label ibuprofen, initial dose of 10 mg/kg, then 2 doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Signs of a hemodynamically significant PDA: Signs of PDA + pulmonary hemorrhage alone or Signs of PDA + Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due to PDA) defined as at least two of the following respirator settings: Need for supplemental O2 \> 50%; need IMV \>40; need for PIP \> 20; or need for HFOV. Infants who had received placebo will ibuprofen for the first time (thus, late ibuprofen or expectant).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Thiamine as a Metabolic Resuscitator After Cardiac Arrest

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patient (age ≥ 18 years)~* Cardiac arrest occurring with sustained (\> 20 minutes) return of spontaneous circulation (ROSC)~* Within 4.5 hours of cardiac arrest event~* Lactate \>/=3~Exclusion Criteria:~* Clinical indication for thiamine administration (alcoholism, known or highly suspected deficiency) or treatment with thiamine beyond the amount found in a standard multivitamin within the last 10 days~* Traumatic etiology of arrest~* Comfort measures only or anticipated withdrawal of support within 24 hours~* Protected populations (pregnant women, prisoners)~* Known allergy to thiamine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Thiamine (Type: EXPERIMENTAL): Patients randomized to the thiamine arm will receive thiamine 500mg in 100mL of normal saline intravenously every 12 hours for 5 doses. Patients will be connected to a noninvasive monitor for measurement of global oxygen consumption (VO2) for at least 48 hours or until extubated, whichever comes first. Blood will be drawn at 0,6,12,24,72 and 168 hours for measurement of lactate, thiamine level, pyruvate dehydrogenase, NSE, S100 and other markers of organ injury. CPC-E score will be assessed prior to hospital discharge and at 30 and 90 days to evaluate differences in neurologic and functional impairment.
- Placebo (Type: PLACEBO_COMPARATOR): Patients randomized to placebo will receive 100mL normal saline intravenously every 12 hours for 5 doses. All other aspects of the protocol will be the same as in the experimental arm. Patients will be connected to a noninvasive monitor for measurement of global oxygen consumption (VO2) for at least 48 hours or until extubated, whichever comes first. Blood will be drawn at 0,6,12,24,72 and 168 hours for measurement of lactate, thiamine level, pyruvate dehydrogenase, NSE, S100 and other markers of organ injury. CPC-E score will be assessed prior to hospital discharge and at 30 and 90 days to evaluate differences in neurologic and functional impairment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: TIME ASPIRIN: Chronotherapy With Aspirin for Reduction of Cardiovascular Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Use of low-dose aspirin (acetylsalicylic acid 80mg \[brand name: acetylsalicylic acid cardio TEVA\]\~)~* Patients using aspirin from an MDD ('Baxter')~* Capacity to give informed consent (IC)~Exclusion Criteria:~* Pregnancy~* Mental or physical disability to fulfil study requirements~* Insufficient knowledge of the Dutch language~* Patients currently participating in another (clinical) trial or study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- aspirin after awakening + placebo before bedtime (Type: OTHER): Acetylsalicylic acid 80 mg once daily, orally. Intake in de morning after awakening. Participants already use acetylsalicylic acid 80 mg once daily due to secondary prevention of cardiovascular disease.~Placebo tablet once daily will be added to their medication. The placebo tablet will be taken before bedtime, orally. The placebo is given throughout the study.
- placebo after awakening +aspirin before bedtime (Type: EXPERIMENTAL): Acetylsalicylic acid 80 mg once daily, orally. The time will be changed form morning to bedtime. Participants already use acetylsalicylic acid 80 mg once daily due to secondary prevention of cardiovascular disease.~Placebo tablet once daily will be added to their medication. The placebo tablet will be taken after awakening, orally. The placebo is given throughout the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Antithrombin III in Infectious Disease Caused by COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
INCLUSION CRITERIA:~1. \>18y of age,~2. Subject or proxy who can provide informed consent~3. Positive SARS-COV-2 by Polymerase Chain Reaction (PCR) or as determined by clinical team~EXCLUSION CRITERIA:~1. Adults or Proxy unable to consent~2. Individuals who are not yet adults (infants, children, teenagers)~3. Pregnant women~4. Prisoners~5. Patients expected to die within 24 hours or with a do not resuscitate order,~6. Multi-organ failure,~7. History of hypersensitivity or allergy to any component of the study drug,~8. Ongoing massive surgical or unexplained bleeding,~9. History of bleeding or clotting disorder,~10. Severe traumatic brain injury (Glasgow Coma Scale \<6),~11. Spinal or multiple-trauma,~12. Cancer (incurable/terminal phase) and/or patients receiving palliative care,~13. Enrollment in another concurrent clinical interventional study if considered interfering with this study objectives~14. Per study team discretion, any condition(s) that may prevent safe treatment, preclude adequate evaluation or adding further risk to their underlying illness.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AT3 less than 100% with SOC plus AT3 supplement (Type: EXPERIMENTAL): Participants in this group, with endogenous Antithrombin lll less than 100%, will receive 5 doses of supplemental Antithrombin III on Days 1, 3, 5, 7 and 9, in addition to standard of care (SOC) treatment.
- AT3 less than 100% with SOC only (Type: NO_INTERVENTION): Participants in this group, with endogenous Antithrombin III less than 100%, will receive SOC treatment only.
- AT3 more than 100% with SOC only (Type: NO_INTERVENTION): Participants in this group, with endogenous Antithrombin III more than 100%, will receive SOC treatment only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of Oral Dehydroepiandrosterone(DHEA) to Treat Previously Unexplained Infertility

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \>= 1 year of infertility~* \< 38 years old~* Normal HSG~* Normal Semen analysis (Count \>= 20 million/ motility \> 50%/ Kruger morph \> 14%.~* Regular menses~* Willingness to sign informed consent for study randomization~* Willingness to participate in 8 months of non-IVF will he him treatment.~Exclusion Criteria:~* Abnormal semen analysis~* Abnormal HSG~* Baseline FSH/E2 within normal age specific criteria~* Medical condition that would contraindicate pregnancy, ovulation induction or general anesthesia~* Family history of significant genetic disease, or factor V leiden thrombophilia~* Inability to present for monitoring visits~* Inability to follow medication instruction~* Desire to undergo other fertility treatments before completing eight months of this trial

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 37 Years
- Healthy Volunteers: t

Study Arms:
- DHEA (Type: EXPERIMENTAL): Dehydroepiandrosterone (DHEA) administered at a dose of 25 mg tid po. DHEA is a weak androgen produced naturally by the adrenal in men and women. DHEA production is diminished with increasing age. Peak levels of DHEA occur in the late teenage years.
- Placebo (Type: PLACEBO_COMPARATOR): Blinded placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Helium/Oxygen Compared to Air/Oxygen in Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with known or suspected COPD~* Patient presenting current exacerbation of COPD with hypercapnic acute respiratory failure~* Patient eligible for Non-Invasive Ventilation (NIV)~* Patient admitted in an ICU~Exclusion Criteria:~* Patient who had lung transplant~* Patient having a contraindication to NIV~* Patient with tracheostomy~* Patient requiring Oxygen flow rate \> 6 L/min or Inspired Oxygen Fraction (FIO2) \> 0.50~* Patient admitted in the ICU for more than 24 hours and/or having received NIV in ICU for more than 6 hours (in total) for the current exacerbation of COPD

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Helium/Oxygen (Type: EXPERIMENTAL): Helium/Oxygen 78%/22% will be administered for a maximum of 72 hours.
- Air/Oxygen (Type: ACTIVE_COMPARATOR): Air/Oxygen will be administered for a maximum of 72 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Acupressure for Insomnia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18-65 years of age~* Meet DSM-IV criteria for primary insomnia~* Insomnia must also be documented on two weeks of a baseline sleep diary~Exclusion Criteria:~* Diagnosis or high clinical suspicion of a sleep disorder other than insomnia~* Evidence of a unstable Axis I psychiatric disorder~* Evidence of an uncontrolled medical disorder or pain syndrome that affects sleep, causes daytime sleepiness, or is likely to be causally associated with the insomnia~* Current pharmacological or non-pharmacological insomnia treatment~* Routine overnight shift work~* Previous failed trial of acupuncture or acupressure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: NO_INTERVENTION): Participants will be asked to continue doing whatever their healthcare providers advise for their insomnia, but not to start any new treatments during the study. They will also be given a sleep hygiene handout as a standard of care. After six weeks, they will be reassessed and then provided the opportunity to engage in the web-based acupressure intervention.
- Relaxation Acupressure (Type: ACTIVE_COMPARATOR): In addition to being given a sleep hygiene handout as a standard of care, participants will be asked to apply pressure on each of following points (bilaterally where indicated). There are 5 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 9 points to stimulate. Each of the 9 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 27 minutes done once daily.
- Stimulating Acupressure (Type: ACTIVE_COMPARATOR): In addition to being given a sleep hygiene handout as a standard of care, participants will be asked to apply pressure on each of following points (bilaterally where indicated). There are 6 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 10 points to stimulate. Each of the 10 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 30 minutes done once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Role of Intravitreal Tissue Plasminogen Activator in Treatment of Refractory Diabetic Macular Edema

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. type 2 diabetes~2. Non proliferative diabetic retinopathy(NPDR) stage of diabetic retinopathy~3. patients with refractory DME CSME (patients with the last MPC at least 3 months before and no improvement was observed in BCVA, macular thickness inOCT, clinical examination and fundus photographs of patients )~4. Absence of PVD in the B-scan~5. Absence of PVD in OCT of macular area and optic disk~6. Absence of PVD in slit lamp biomicroscopy(SLE)~7. the last PRP session was at least 3 months ago.~8. Absence of traction on macula in clinical examination and OCT~Exclusion Criteria:~1. One eye patients~2. Patients who are candidates for intraocular surgery.~3. Patients with the history of glaucoma or ocular hypertension~4. Patients with a history of vitrectomy in the study eye~5. Not being able to refer for the next visits~6. Eyes with cataract that makes the assessment of the macula impossible.~7. Intraretinal hemorrhage at fovea that will interfere with OCT.~8. BCVA ≤ 0.1

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TPA,IVB,F/U (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Long Term Follow-up Study in Participants Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participant was randomized to a regimen containing Odalasvir (ODV) with AL-335 with or without Simeprevir in a preceding Phase 2 or Phase 3 study (parent study)~* Participant received at least 1 dose of ODV with AL-335 with or without SMV in the parent study~* Participant has completed the last post-therapy follow-up visit of the parent study ( LPVPS) and has not passed the screening period of 6 + 3 months after the LPVPS~* Participant has signed an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and is willing to participate in the study~Exclusion Criteria:~* Participant is currently enrolled or plans to enroll in another study with an investigational drug (including investigational vaccines) or an invasive investigational medical device between the LPVPS and Visit 6 of the present study (36 months (+/-) 4 weeks after the LPVPS of the parent study)~* Participant received antiviral or immunomodulating treatment, including therapeutic vaccines, for HCV infection between the LPVPS and the screening visit of the present study, or is planned to receive such treatment during the period of this follow-up study~* Participant is not able to adhere to the requirements of the follow-up study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Odalasvir and AL-335 With or Without Simeprevir (Type: OTHER): Participants who completed the LPVPS (Phase 2 or Phase 3 study), in which they received a regimen containing Odalasvir and AL-335 With or Without Simeprevir for the treatment of HCV infection, and who agree to participate in this follow-up study will be assessed for durability of SVR, incidence of late viral relapse, presence and long term-persistence of resistance associated substitutions (RAS) and liver disease status.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues